New hope for rare clotting disorder: drug targets antibody levels
NCT ID NCT06315530
First seen Feb 01, 2026 · Last updated Apr 25, 2026 · Updated 8 times
Summary
This study tested a drug called telitacicept in 20 adults with antiphospholipid syndrome (APS), a condition where the immune system mistakenly attacks healthy cells, raising the risk of blood clots. The goal was to see if the drug could lower high-risk antibody levels over 48 weeks. Researchers also monitored for new clots and studied immune cell changes. The trial was completed and may lead to better ways to manage APS.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME (APS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ruijin Hospital
Shanghai, Shanghai Municipality, 200025, China
Conditions
Explore the condition pages connected to this study.